Current targeted therapies in the treatment of advanced colorectal cancer: a review
Open Access
- 29 May 2016
- journal article
- review article
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 8 (4) , 276-293
Abstract
Treatment strategies for metastatic colorectal cancer (mCRC) patients have undergone dramatic changes in the past decade and despite improved patient outcomes, there still exist areas for continued development. The introduction of targeted agents has provided clinicians with additional treatment options in mCRC, however, results have been mixed at best. These novel therapies were designed to interfere with specific molecules involved in the cellular carcinogenesis pathway and ultimately deliver a more focused treatment. Currently, their use in mCRC has been limited primarily as an adjunct to conventional chemotherapy regimens. This review explores the relevant cell-signaling networks in colorectal cancer, provides focus on the current targeted agent armamentarium approved for use in mCRC and explores the usefulness of predictive mCRC biomarkers.Keywords
This publication has 164 references indexed in Scilit:
- An Update on the Current and Emerging Targeted Agents in Metastatic Colorectal CancerClinical Colorectal Cancer, 2012
- Development of Second-Generation VEGFR Tyrosine Kinase Inhibitors: Current StatusCurrent Oncology Reports, 2011
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysisThe Lancet Oncology, 2010
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008International Journal of Cancer, 2010
- Cell Signaling by Receptor Tyrosine KinasesCell, 2010
- Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survivalThe Lancet Oncology, 2010
- ERBBs in the gastrointestinal tract: Recent progress and new perspectivesExperimental Cell Research, 2009
- Structural basis for inhibition of the epidermal growth factor receptor by cetuximabCancer Cell, 2005
- EGFR and cancer prognosisEuropean Journal of Cancer, 2001
- Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivoNature, 1993